Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: Where are we now?
- 30 June 2005
- journal article
- editorial
- Published by Elsevier in Neuromuscular Disorders
- Vol. 15 (6) , 399-402
- https://doi.org/10.1016/j.nmd.2005.03.003
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Finishing the euchromatic sequence of the human genomeNature, 2004
- Readthrough of dystrophin stop codon mutations induced by aminoglycosidesAnnals of Neurology, 2004
- Autoregulation of Polypyrimidine Tract Binding Protein by Alternative Splicing Leading to Nonsense-Mediated DecayPublished by Elsevier ,2004
- Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophyNeuromuscular Disorders, 2002
- Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutationsAnnals of Neurology, 2001
- Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx miceJournal of Clinical Investigation, 1999
- Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotidesNeuromuscular Disorders, 1999
- Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotidesHuman Molecular Genetics, 1998
- Duchenne phenotype with in-frame deletion removing major portion of dystrophin rod: Threshold effect for deletion size?Muscle & Nerve, 1996
- Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individualsCell, 1987